

**IN THE CLAIMS:**

Claims 22 and 25 have been amended herein. All of the pending claims 1, 2, 4-16, 22 and 25 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

1. (previously presented) A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP3.

2. (previously presented) A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP3, having a modified translation initiation site directly upstream of the ATG-initiation codon of said nucleic acid molecule, wherein said translation initiation site comprises the nucleic acid sequence GCCAAC.

3. (Canceled)

4 (previously presented) A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP2.

5. (previously presented) A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP2, having a modified translation initiation site directly upstream of the ATG-initiation codon of said nucleic acid molecule, wherein said translation initiation site comprises the nucleic acid sequence GCCAAC.

6. (previously presented) The gene delivery vehicle according to claim 1 additionally comprising a nucleic acid molecule encoding chicken anemia virus protein VP2.

7. (previously presented) The gene delivery vehicle according to claim 2 additionally comprising a nucleic acid molecule encoding chicken anemia virus protein VP2, having a modified translation initiation site directly upstream the ATG-initiation codon of the nucleic acid molecule encoding chicken anemia virus protein VP2, wherein said translation initiation site comprises the nucleic acid sequence GCCAAC.

8. (previously presented) The gene delivery vehicle according to claim 1 which is a viral vector.

9. (previously presented) The gene delivery vehicle according to claim 8 wherein said viral vector is replication defective.

10. (previously presented) The gene delivery vehicle according to claim 9 wherein said viral vector is an adenoviral vector.

11. (previously presented) The gene delivery vehicle according to claim 9 wherein said viral vector is a retroviral vector.

12. (previously presented) The gene delivery vehicle according to claim 6 which additionally comprises at least one target molecule.

13. (previously presented) The gene delivery vehicle according to claim 12 wherein the target molecule is reactive with a tumor cell surface receptor.

14. (previously presented) A host cell comprising the gene delivery vehicle according to claim 13.

15. (previously presented) The host cell according to claim 14 which is a helper or packaging cell.

16. (previously presented) The host cell according to claim 14 which is selected from the group of HEK 293, HER 911, PER-C6, Psi-2, and PA-317 cells.

17-21. (Canceled)

22. (currently amended) A method for inducing apoptosis in a mammalian tumor by directly administering to ~~the~~ a tumor of a mammal the gene delivery vehicle of claim 1 ~~to a mammal~~.

23-24. (Canceled)

25. (currently amended) A method for inducing apoptosis in a mammalian tumor by directly administering to ~~the~~ a tumor of a mammal the gene delivery vehicle of claim 6 ~~to a mammal~~.

26-27. (Canceled)